Navigation Links
Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
Date:8/3/2011

ROCKVILLE, Md., Aug. 3, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced it received a U.S. Department of Defense (DOD) contract to develop its human neural stem cell technology for the treatment of cancerous brain tumors. The research contract, entitled "Research to Treat Cancerous Brain Tumors with Neural Stem Cells," will be carried out in collaboration with Principal Investigator John Zhang, MD, PhD, Professor of Neurosurgery, Loma Linda University, in Loma Linda, CA. The contract award is $1.6 million for the first year of the project, of which Neuralstem will receive $625,000.  The DOD has three one-year options to continue the program after the first year based upon milestones.  The goal of the program is to have a therapeutic product for the treatment of cancerous brain tumors ready to submit to the FDA by the end of the fourth year (2015).

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"Current cancer therapies do not work on the majority of  brain tumors.  The prognosis for patients with a brain tumor such as glioblastoma is about 12 months of life," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer. "We will be engineering our cells to attack brain cancer in three ways: first, by expressing an antibody known to suppress tumor growth; second, by expressing an enzyme that selectively kills tumor cells; and third by expressing an antiangiogenic protein that will starve the tumors by preventing the formation of the blood vessels that feed them.

"We believe that transplantation of our cells into the brain provides a unique route of administration through which to deliver these three anti-tumor therapies.  Neural stem cells are known to migrate to tumors and thus should be particularly well suited to the task.  Additionally, because we are transplanting the cells directly into
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
2. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
3. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
4. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
5. Neuralstem Completes $5.25 Million Financing
6. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
7. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
9. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
10. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
11. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 SonaCare ... focused ultrasound (HIFU) technology, announced that its Board ... as Chief Executive Officer, President and member of ... Dr. Carol will take-on expanded responsibilities within the ... as well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... 25, 2014 Berkshire Corporation, the ... to announce the release of the ValuSeal® IonX™ ... of contamination containment in critical processing applications. , ... higher cleanroom environments, ValuSeal® IonX™ is a laser ... wiper that continues Berkshire’s innovative focus on meeting ...
(Date:10/25/2014)... and NEW YORK ... Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), ... areas, announced it has implemented a 1-for-50 reverse ... opening of trading on Friday, October 24, 2014. ... basis under new CUSIP number 72754H109 and temporary ...
(Date:10/25/2014)... LONDON , October 24, 2014 ... CytRx Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals ... (NASDAQ: ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 23, 2014, ended on a positive ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... daily recommended dosages of ibuprofen and acetaminophen caused a ... quadriceps muscle mass and muscle strength gained during three ... physiologists at the Human Performance Laboratory, Ball State University. ... working with Dr. Todd Trappe, reported study results at ...
... Laboratory will host the inaugural conference of the ... create a virtual center in cyberspace for plant ... "Bringing Plant and Computing Scientists Together to Solve ... 7-9, 2008, will take the first steps in ...
... As the saying goes, some people are born with ... at least one species of the animal world, according ... Alberta. A study of female red squirrels in ... as food availability and spring temperature experienced between birth ...
Cached Biology News:Ibuprofen or acetaminophen in long-term resistance training increases muscle mass/strength 2iPlant Kickoff Conference at CSHL begins tackling plant biology's grand challenges 2iPlant Kickoff Conference at CSHL begins tackling plant biology's grand challenges 3
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: